GlassScriptPhysician profile
Anna I Vanderheiden
NPI 1740414630
$179,218.62
in general payments reported to CMS, 2019-2025
44 companies · $57K in 2025
The $57K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $22K · 2021: $21K · 2022: $39K · 2023: $20K · 2024: $19K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Consulting Fee: $7,045 · Food and Beverage: $6,748 · Travel and Lodging: $4,680 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,301.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,044.00 |
| Consulting Fee | $7,045.00 |
| Food and Beverage | $6,747.91 |
| Travel and Lodging | $4,680.13 |
| Education | $308.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $140,791.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $19,986.90 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $10,977.93 | 2019-2025 | |
| Insulet Corporation | $2,082.98 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $2,081.93 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $546.48 | 2019-2025 | Prolia, Tepezza, Evenity |
| Lilly USA, LLC | $337.16 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Averitas Pharma INC. | $225.77 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $193.48 | 2023 | |
| Intuitive Surgical, INC. | $158.11 | 2023 | Da Vinci Surgical System |
| Abbott Laboratories | $130.57 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $123.83 | 2019-2020 | |
| Esperion Therapeutics, INC. | $117.58 | 2021-2024 | Nexletol |
| Sequel Med Tech, LLC | $99.92 | 2025 | Twiist |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $95.82 | 2022 | |
| Corcept Therapeutics | $87.67 | 2025 | Korlym |
| Radius Health, INC. | $79.30 | 2022-2024 | Tymlos |
| Mannkind Corporation | $72.28 | 2024-2025 | |
| Beta Bionics, INC. | $70.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Perspectum Diagnostics LTD | $64.36 | 2023 | Livermultiscan |
| Neurocrine Biosciences, INC. | $61.33 | 2024-2025 | |
| Medtronic, INC. | $60.34 | 2023 | Inpen Smart Insulin Delivery System |
| Soleno Therapeutics, INC. | $51.68 | 2025 | Vykat Xr |
| Ascendis Pharma Endocrinology INC | $49.68 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $46.59 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $45.72 | 2022-2023 | Tepezza |
| Cequr Corporation | $42.66 | 2023-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.96 | 2019-2023 | |
| Madrigal Pharmaceuticals | $41.85 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $40.81 | 2022-2024 | Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $36.28 | 2025 | Unithroid |
| Globus Medical, INC. | $30.57 | 2025 | Senza |
| Medtronic Minimed, INC. | $28.00 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $26.45 | 2023 | |
| Merck Sharp & Dohme LLC | $25.71 | 2019 | |
| Astellas Pharma US INC | $21.40 | 2024 | Veozah |
| Halozyme INC | $19.86 | 2023 | |
| Abbvie INC. | $19.02 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.94 | 2025 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $15.70 | 2025 | Contrave |
| Shire North American Group INC | $15.34 | 2019 | |
| Companion Medical, INC. | $15.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Vanderheiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.